对保护性miRNA进行查,并构建新的lncRNA/miRNA/mRNA网络和预后模型,用于三阴性乳腺癌
Yuelei Zhao1, Yichen Song1, Yan Zhang1
1Department of Endocrinology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi Province, PR China.
Molecular and cellular probes
|October 23, 2023
概括
研究人员发现,与其他乳腺癌相比,微RNA (miRNA) 在三阴性乳腺癌 (TNBC) 中具有相反的生存关联. 他们开发了一种用于TNBC预后的3miRNA模型,将IRS-1确定为关键目标基因.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 三重阴性乳腺癌 (TNBC) 的预后不好,缺乏向治疗.
- 微RNAs (miRNAs) 参与TNBC进展,但它们的表达和功能是异质的.
- 识别新的分子标对于改善TNBC预后和治疗至关重要.
研究的目的:
- 分析TNBC中的miRNA表达模式,并确定预后生物标志物.
- 开发TNBC患者整体生存预测模型.
- 阐明涉及miRNAs,lncRNAs和mRNAs在TNBC中的调节网络.
主要方法:
- 来自癌症基因组图谱 (TCGA) 的miRNA表达数据的分析.
- 应用单变量和多变量考克斯比例危险回归模型.
- 使用转录组数据构建一个lncRNA-miRNA-mRNA调节网络.
- 在体外验证miRNA-目标相互作用和功能测试.
主要成果:
- 过度表达的miRNA与TNBC的更好的生存率有关,与其他乳腺癌形成鲜明对比.
- 一个3-miRNA预后模型显示AUC为0.727用于预测TNBC总生存期.
- IRS-1被确定为一个顶部枢纽基因,由miR-15b-5p和miR-148a-3p作为目标.
- miR-148a-3p显著抑制了TNBC细胞迁移和活力.
结论:
- 识别的3-miRNA模型为TNBC风险评估和临床应用提供了强大的工具.
- 这项研究揭示了对TNBC异质miRNA景观的新见解.
- 准特定的miRNA及其下游通路,如IRS-1,有可能为TNBC特异性疗法提供潜力.
相关概念视频
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K


